GlassScriptPhysician profile
David A Mattingly
NPI 1558328443
$198,376.16
in general payments reported to CMS, 2019-2025
12 companies · $172 in 2025
The $172 reported for 2025 was less than what a typical Adult Reconstructive Orthopaedic Surgery provider received nationally (typical 2025 total: $1,425).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47K · 2020: $41K · 2021: $44K · 2022: $46K · 2023: $20K · 2024: $349 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $20K · Food and Beverage: $522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $19,508.49 |
| Food and Beverage | $521.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Products, INC. | $196,366.47 | 2019-2023 | Reclaim |
| Medical Device Business Services, INC. | $1,026.82 | 2019-2024 | Attune |
| Stryker Corporation | $606.15 | 2019-2025 | Mako |
| Zimmer Biomet Holdings, INC. | $112.60 | 2020 | |
| Depuy Synthes Sales INC. | $72.35 | 2020-2024 | Monovisc |
| Pacira Therapeutics, INC. | $47.13 | 2019 | |
| Baudax Bio INC. | $34.25 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $28.06 | 2020 | |
| Ethicon US, LLC | $24.57 | 2019 | |
| Convatec INC. | $22.53 | 2019 | |
| Ferring Pharmaceuticals INC. | $20.71 | 2020 | |
| Sanofi-Aventis U.S. LLC | $14.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mattingly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.